Newsroom

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

PDF Version MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that two Medicare Administrative Contractors (MACs), Novitas Solutions, Inc. (Novitas) and First […]

read more +
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy profiles make OMNI a beneficial treatment option for patients with primary open-angle glaucoma MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology […]

read more +
Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments

UnitedHealthcare’s Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform […]

read more +
Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data MENLO PARK, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional […]

read more +
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

PDF Version MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference […]

read more +
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue […]

read more +
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

PDF Version Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research MENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced the […]

read more +
Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

PDF Version Mean signs and symptoms for participants in Stage 3 of the SAHARA trial remained statistically significantly better than study baseline at all time points measured up to 24 months MENLO PARK, Calif., July 29, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused […]

read more +